The Ontario Public Drug Programs (OPDP) began funding INFLECTRA™ (infliximab) as a Limited Use (LU) benefit for eligible ODB recipients, effective February 25, 2016, for the following indications:
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Psoriatic Arthritis
- Plaque Psoriasis
The LU criteria are posted in the eFormulary which can found on the ministry’s website at:
http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx
The funding of REMICADE (infliximab) remains unchanged and recipients with existing approvals under the Exceptional Access Program can continue to access REMICADE.
For more information, please call ServiceOntario, INFOline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559
In Toronto, TTY (416) 327-4282